Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XXL: Xevinapant with RT and Cetuximab in LA SCCHN
NCT05930938Phase 3Terminated
- Sponsor
- GORTEC
- Start
- Dec 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of xevinapant in squamous cell carcinoma of the head and neck (HNSCC), sponsored by GORTEC. Started Dec 2023; status: terminated.
02
Drugs
xevinapant
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT05930938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05930938.